<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Natco Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/natco-pharma-limited</link>
<description>Latest news and press releases for Natco Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 20 Mar 2026 13:31:20 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/natco-pharma-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364d4178dffbe2df1540b4.webp</url>
<title>Natco Pharma Limited</title>
<link>https://6ix.com/company/natco-pharma-limited</link>
</image>
<item>
<title>Press Release Mar 20 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-mar-20-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-mar-20-2026-5</guid>
<pubDate>Fri, 20 Mar 2026 13:31:20 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated March 20, 2026, titled "NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290".</description>
</item>
<item>
<title>Press Release Mar 03 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-mar-03-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-mar-03-2026-5</guid>
<pubDate>Tue, 03 Mar 2026 15:29:43 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated March 03, 2026, titled "NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market".</description>
</item>
<item>
<title>Press Release Feb 14 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-feb-14-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-feb-14-2026-1</guid>
<pubDate>Sat, 14 Feb 2026 14:31:18 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "NATCO receives approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India".</description>
</item>
<item>
<title>Press Release Feb 13 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-feb-13-2026-15</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-feb-13-2026-15</guid>
<pubDate>Fri, 13 Feb 2026 14:18:23 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release regarding the receipt of Establishment Inspection Report (EIR) for the API Unit located in Chennai from U.S. Food and Drug Administration (FDA)".</description>
</item>
<item>
<title>Press Release Feb 03 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-feb-03-2026-14</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-feb-03-2026-14</guid>
<pubDate>Tue, 03 Feb 2026 19:50:20 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa®) from the United States Food and Drug Administration (U.S. FDA)".</description>
</item>
<item>
<title>Press Release Jan 30 2026</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-jan-30-2026-26</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-jan-30-2026-26</guid>
<pubDate>Fri, 30 Jan 2026 17:43:57 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015".</description>
</item>
<item>
<title>Press Release Nov 21 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-nov-21-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-nov-21-2025-8</guid>
<pubDate>Fri, 21 Nov 2025 21:15:55 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated November 21, 2025, titled "Conclusion of FDA Inspection at our Manali, Chennai API Unit".</description>
</item>
<item>
<title>Press Release Nov 12 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-nov-12-2025-14</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-nov-12-2025-14</guid>
<pubDate>Wed, 12 Nov 2025 20:02:29 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Adcock Ingram Holdings Limited completes delisting from Johannesburg Stock Exchange and NATCO Pharma Limited acquires 35.75% stake".</description>
</item>
<item>
<title>Press Release Oct 31 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-oct-31-2025-15</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-oct-31-2025-15</guid>
<pubDate>Fri, 31 Oct 2025 13:02:58 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated October 31, 2025, titled "NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)".</description>
</item>
<item>
<title>Press Release Oct 17 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-oct-17-2025-24</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-oct-17-2025-24</guid>
<pubDate>Fri, 17 Oct 2025 21:08:57 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated October 17, 2025, titled "Legal update regarding Risdiplam ".</description>
</item>
<item>
<title>Press Release Oct 10 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-oct-10-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-oct-10-2025-6</guid>
<pubDate>Fri, 10 Oct 2025 17:07:09 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated October 10, 2025, titled "Updates on proposed acquisition of shares in Adcock Ingram Holdings Limited".</description>
</item>
<item>
<title>Press Release Oct 09 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-oct-09-2025-9</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-oct-09-2025-9</guid>
<pubDate>Thu, 09 Oct 2025 21:32:41 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated October 09, 2025, titled "Legal update regarding Risdiplam Commercial Appellate Division of the Hon ble Delhi High Court Dismissed Appeal ".</description>
</item>
<item>
<title>Press Release Sep 18 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-sep-18-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-sep-18-2025-6</guid>
<pubDate>Thu, 18 Sep 2025 13:50:47 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "NATCO's Pharma division located in Kothur, Hyderabad, India has now received Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated (VAI)" from the U.S. Food and Drug Administration (FDA)</description>
</item>
<item>
<title>Press Release Sep 10 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-sep-10-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-sep-10-2025-6</guid>
<pubDate>Wed, 10 Sep 2025 15:19:02 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated September 10, 2025, titled "Update".</description>
</item>
<item>
<title>Press Release Aug 20 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-aug-20-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-aug-20-2025-4</guid>
<pubDate>Wed, 20 Aug 2025 14:48:03 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated August 20, 2025, titled "NATCO launches Bosentan Tablets for Oral Suspension (generic of Tracleer®) in the United States with 180-day exclusivity".</description>
</item>
<item>
<title>Press Release Jul 24 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-jul-24-2025-22</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-jul-24-2025-22</guid>
<pubDate>Thu, 24 Jul 2025 18:00:13 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "NATCO Pharma Limited, API unit in Mekaguda Receives Establishment Inspection Report (EIR) from U.S. FDA".</description>
</item>
<item>
<title>Press Release Apr 08 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-apr-08-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-apr-08-2025-6</guid>
<pubDate>Tue, 08 Apr 2025 15:04:21 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated April 08, 2025, titled "Legal Update regarding RISDIPLAM launch in India.".</description>
</item>
<item>
<title>Press Release Feb 10 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-feb-10-2025-20</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-feb-10-2025-20</guid>
<pubDate>Mon, 10 Feb 2025 14:12:38 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated February 10, 2025, titled "NATCO announces final approval of its ANDA for Bosentan tablets".</description>
</item>
<item>
<title>Press Release Jan 30 2025</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-jan-30-2025-21</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-jan-30-2025-21</guid>
<pubDate>Thu, 30 Jan 2025 14:33:29 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated January 30, 2025, titled "NATCO announces approval of its ANDA for Everolimus tablets".</description>
</item>
<item>
<title>Press Release Nov 27 2024</title>
<link>https://6ix.com/company/natco-pharma-limited/news/press-release-nov-27-2024-8</link>
<guid isPermaLink="true">https://6ix.com/company/natco-pharma-limited/news/press-release-nov-27-2024-8</guid>
<pubDate>Wed, 27 Nov 2024 22:53:02 GMT</pubDate>
<description>Natco Pharma Limited has informed the Exchange regarding a press release dated November 27, 2024, titled "Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015".</description>
</item>
</channel>
</rss>